Note: Ingredients listed on restricted chemical lists
EC/CAS
500-033-5/25068-38-6
Name of the chemical
4,4'-Isopropylidenediphenol, oligomeric reaction products with 1-chloro-2,3-epoxypropane
Concentration
30 - 50
General Information
Version
7.1
Revision date
2022-05-12
Product name
GLASSFLO 785 PART A
1.2.1 Relevant identified uses
Professional use,Industrial use Industrial/Professional use spec Industrial
Manufacturer Name
ROCOL a division of ITW Ltd
Emergency telephone
+44 (0)113 232 2600, 0344 892 0111
Icons in SDS
Company Information
company name
ROCOL a division of ITW Ltd
e-mail address of the competent person responsible for the Safety Data Sheet
customer.service@rocol.com
GHS Information
Signal word
Warning
Hazard Codes
Hazard statements (CLP)
H315, H317, H319, H411
Hazard statements
Code
Statements
H315
Causes skin irritation
Section 2
SECTION 2: Hazards identification
Adverse physicochemical, human health and environmental effects
No additional information available
2.2 Label elements
Labelling
Hazard pictograms
GHS07 GHS09
Signal word
: Warning
Contains
: BISPHENOL A-(EPICHLORHYDRIN) {REACTION PRODUCT}
Hazard statements
: H315 - Causes skin irritation. H317 - May cause an allergic skin reaction. H319 - Causes serious eye irritation. H411 - Toxic to aquatic life with long lasting effects.
Precautionary statements
: P261 - Avoid breathing dust/fume/gas/mist/vapours/spray. P264 - Wash hands, forearms and face thoroughly after handling. P280 - Wear protective gloves/protective clothing/eye protection/face protection/hearing protection. P333+P313 - If skin irritation or rash occurs: Get medical advice/attention. P337+P313 - If eye irritation persists: Get medical advice/attention. P362+P364 - Take off contaminated clothing and wash it before reuse. P391 - Collect spillage.
2.3 Other hazards
Contains no PBT/vPvB substances ≥ 0.1% assessed in accordance with REACH Annex XIII The mixture does not contain substance(s) included in the list established in accordance with Article 59(1) of REACH for having endocrine disrupting properties, or is not identified as having endocrine disrupting properties in accordance with the criteria set out in Commission Delegated Regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at a concentration equal to or greater than 0,1 %
